share_log

Morgan Stanley Maintains Equal-Weight on Nautilus Biotechnology, Lowers Price Target to $6

Benzinga Real-time News ·  Aug 3, 2022 10:00

Morgan Stanley analyst Tejas Savant maintains Nautilus Biotechnology (NASDAQ:NAUT) with a Equal-Weight and lowers the price target from $8 to $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment